- Details
- Description
-
Packaging Size60t/bottle
-
Strength450mg
-
CompositonValganciclovir
-
TreatmentCytomegalovirus (CMV）
-
FormTablet
-
BrandLuciValgan
-
Quantity Unit450mg*60t/Box
-
ManufacturerLucius Pharmaceuticals (Lao) Co.,Ltd
About Valganciclovir
Valganciclovir is an antiviral medication used to treat cytomegalovirus (CMV) infection in those with HIV/AIDS or following organ transplant (eg, heart, kidney, or kidney-pancreas transplant).
It is often used long term as it only suppresses rather than cures the infection.
Cytomegalovirus Retinitis
Indicated for treatment of CMV retinitis in patients with AIDS
Induction dose: 900 mg PO q12hr for 21 days
Maintenance dose: Following induction treatment, or in adults with inactive CMV retinitis, 900 mg PO qDay
CMV Colitis or Esophagitis in HIV-Infected Patients (Off-label)
Treat initially with ganciclovir 5 mg/kg/dose IV q12hr; once therapy is tolerated, change to valganciclovir 900 mg PO q12hr for 21-42 days or until signs and symptoms have resolved
CMV Prevention in Solid Organ Transplant
Indicated for the prevention of CMV disease in kidney, heart, and kidney-pancreas transplant patients at high risk (donor CMV seropositive/recipient CMV seronegative [D+/R-])
Kidney transplantation
- 900 mg PO qDay
- Begin within 10 days of transplant until 200 days post-transplant
Kidney-pancreas transplantation
- 900 mg PO qDay
- Begin within 10 days of transplant until 100 days post-transplant
Heart transplantation
- 900 mg PO qDay
- Begin within 10 days of transplant until 100 days post-transplant
Dosage Modifications
Hepatic impairment: Safety and efficacy not established
Renal impairment
- CrCl 40-59 mL/min: 450 mg PO q12hr (induction), THEN 450 mg qDay
- CrCl 25-39 mL/min: 450 mg PO qDay (induction), THEN 450 mg q2days
- CrCl 10-24 mL/min: 450 mg PO q2days (induction), THEN 450 mg 2 times/week
- <10 mL/min (on hemodialysis): Not recommended
Dosing Considerations
Adults should use tablets, not oral solution
Lymphoproliferative Disorder (Orphan)
Orphan designation for treatment of post-transplant lymphoproliferative disorder in combination with nanatinostat
